Cheers Oilandgasman,
Amyndas has AMY-101, a C3 complement inhibitor and has orphan drug designation for a very rare condition called C3 glomerulopathy. Although, this condition does result in proteinuria (as do all diseases of the kidney that affect the glomerulus), this is a very different disease to FSGS and CKD nephropathy in general. The mechanism is also very different. So in summary- AMY-101 is playing in a different paddock to DMX-200- not in real competition.
- Forums
- ASX - By Stock
- DXB
- Dimerix vs Amyndas
Dimerix vs Amyndas, page-2
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M |
Open | High | Low | Value | Volume |
45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 111371 | 44.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.0¢ | 8072 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.445 |
2 | 11800 | 0.440 |
1 | 2873 | 0.435 |
6 | 51845 | 0.430 |
5 | 363850 | 0.425 |
Price($) | Vol. | No. |
---|---|---|
0.455 | 69140 | 3 |
0.460 | 129800 | 5 |
0.465 | 109385 | 4 |
0.470 | 37222 | 3 |
0.475 | 10000 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |